Kjell Johanssen was named to the newly created position of COO at Recipharm in August, to oversee ops development and growth of the contract manufacturing business. He had previously spent 20 years at AstraZeneca in senior manufacturing and supply chain roles.
Recipharm appears to be on a bit of a rally. It was just named a finalist in two categories in the European Outsourcing Awards 2011: "Most improved process/plant facility" and "Most effective drug discovery/development program."
The Nice scores reflect a rally: Recipharm's 76% CP rating for Q3 is a 6% rise over Q2 and a 20% rise over Q1. Companion CA scores show a similar trend: Q3's 50% is 13% higher than Q2's and 19% higher than Q1's.
The privately owned CMO offers drug development (clinical supply through formulation) and manufacturing services, in addition to services for EU import, regulatory assistance and logistics and packaging. It has facilities across Europe--in Sweden, France, the UK, Germany and Spain--and employs about 1,800. A development center in Solna, Stockholm, has its own GMP pilot facility for solid dose, semi-solids and sterile formulations.